吉西他滨联合卡培他滨治疗晚期乳腺癌的临床观察  

Clinical observation on the clinical effect of Gemcitabine combined with Capecitabine in treatment of advanced breast cancer

作　　者：关萌[1] 周美美[1] 宋艳秋[1] 

机构地区：[1]吉林大学第一医院肿瘤中心,吉林长春130021

出　　处：《中国妇幼保健》2014年第9期1442-1444,共3页Maternal and Child Health Care of China

摘　　要：目的:探讨吉西他滨联合卡培他滨(GX)方案治疗晚期乳腺癌的疗效及不良反应,并与含蒽环类和紫杉类(AT)方案进行比较。方法:收集女性晚期乳腺癌患者73例,其中38例患者应用GX方案治疗,35例患者应用含AT方案治疗,分析比较两组的近期疗效及不良反应。结果:GX组有效率为26.31%,明显低于含AT组71.4%,而临床获益率(97.4%vs 97.1%)及中位疾病进展时间(7个月vs 8个月)未见明显差异。GX组骨髓抑制、胃肠道反应及脱发等均较含AT组轻,而手足综合征较含AT组发生率高,但没有Ⅲ-Ⅳ级手足综合征的发生。结论:吉西他滨联合卡培他滨方案是治疗晚期乳腺癌的有效方案,安全性良好。Objective： To explore the curative effect and adverse reactions of Gemcitabine combined with Capecitabine （GX） in treatment of advanced breast cancer, and compare with Anthracycline and Taxane （AT） . Methods： A total of 73 female patients with ad- vanced breast cancer were collected, including 38 patients treated with GX and 35 patients treated with AT; the short -term curative effects and adverse reactions in the two groups were analyzed and compared. Results： The effective rate in GX group was 26. 31%, which was statistically significantly lower than that in AT group （71.4%） . There was no statistically significant difference in the clinical benefit rate （97.4% vs 97.1% ） and median TTP （7 months vs 8 months） between the two groups; Adverse reactions in GX group such as bone marrow suppression, gastrointestinal reactions and hair loss were milder that those in AT group, the incidence rate of hand - foot syndrome （HFS） was higher than that in AT group, but no III - IV degree HFS occurred. Conclusion： Gemcitabine combined with Capecitabine is an active and safe regimen for advanced breast cancer patients.

关 键 词：吉西他滨 卡培他滨 晚期乳腺癌 近期疗效 不良反应 

分 类 号：R737.9[医药卫生—肿瘤]